Literature DB >> 8456320

Treatment of factor VIII inhibitors: products and strategies.

B G Macik1.   

Abstract

Treatment of patients with inhibitors to FVIII remains a complex clinical problem. Although characterizing the individual patient may aid in the initial development of a care plan, no treatment is uniformly reliable for all patients. Experts in the field are as likely to disagree as agree when it comes to choosing treatment options; few randomized clinical trials exist on which to base decisions.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8456320     DOI： 10.1055/s-2007-994002

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN： 0094-6176            Impact factor:   4.180


  6 in total

1.  Severe bleeding in a patient with spontaneous factor VIII inhibitor and acute exacerbation of chronic pancreatitis.

Authors:  C Martínez; J Mateo; M Pérez; J Errando; E Quintana; J Fontcuberta
Journal:  Intensive Care Med       Date:  1996-11       Impact factor: 17.440

2.  Tolerance to factor VIII inhibitors in hemophilia A patients: a French twist.

Authors:  V Pascual; J D Capra
Journal:  J Clin Invest       Date:  1996-03-15       Impact factor: 14.808

3.  Clinical trial to investigate the pharmacokinetics, pharmacodynamics, safety, and efficacy of recombinant factor VIIa in Japanese patients with hemophilia with inhibitors.

Authors:  A Shirahata; T Kamiya; J Takamatsu; T Kojima; K Fukutake; M Arai; H Hanabusa; H Tagami; A Yoshioka; G M Shima; G H Naka; G S Fujita; Y Minamoto; J Kamizono; H Saito
Journal:  Int J Hematol       Date:  2001-06       Impact factor: 2.490

Review 4.  Varied immune response to FVIII: presence of proteolytic antibodies directed to factor VIII in different human pathologies.

Authors:  Bharath Wootla; Desirazu Narasimha Rao; Narasimha Rao Desirazu; Alain Friboulet; Taizo Uda; Sébastien Lacroix-Desmazes; Srini V Kaveri
Journal:  Clin Rev Allergy Immunol       Date:  2009-10       Impact factor: 8.667

5.  Cost-of-illness study of severe haemophilia A and B in five French haemophilia treatment centres.

Authors:  Virginie Nerich; Edgar Tissot; Albert Faradji; Karine Demesmay; Marie Anne Bertrand; Jean-Louis Lorenzini; Marie-Elisabeth Briquel; Patricia Pouzol; Marie-Christine Woronoff-Lemsi
Journal:  Pharm World Sci       Date:  2007-12-18

6.  Medical costs and hospital utilization for hemophilia A and B urban inpatients in China: a national cross-sectional study.

Authors:  Zhengwei Huang; Stephen Nicholas; Yong Yang; Xiaoping Chen; Elizabeth Maitland; Yong Ma; Xuefeng Shi
Journal:  BMC Health Serv Res       Date:  2022-02-19       Impact factor: 2.655
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.